Compare Page
Selank vs Semax
Quick verdict: Selank and Semax are both Russian-developed regulatory peptides with nootropic and neuroprotective properties, but they work through distinct mechanisms. Selank is derived from the endogenous immunomodulatory peptide tuftsin and primarily modulates GABAergic and serotonergic systems, making it more anxiolytic in character. Semax, derived from ACTH(4–10), acts predominantly through BDNF upregulation and melanocortin pathways, giving it a sharper cognitive-enhancement profile.
Read the full peptide profiles: Selank | Semax.
At a Glance: Selank vs Semax
Mechanism of Action
Selank is a synthetic analog of tuftsin (threonyl-lysyl-prolyl-arginine), a naturally occurring immunomodulatory peptide derived from the heavy chain of immunoglobulin G. The addition of a D-arginine residue stabilises the molecule against enzymatic degradation. Selank’s primary neurotropic effects stem from its modulation of GABAergic neurotransmission — research indicates it enhances GABA-A receptor sensitivity and influences the balance of serotonin and its metabolites in the brain. It also inhibits enkephalinase, which increases the availability of endogenous enkephalins in the CNS, contributing to its anxiolytic character.
Semax, by contrast, is derived from the ACTH(4–10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with a stabilising C-terminal Pro-Gly-Pro tripeptide extension. Unlike full-length ACTH, Semax has no steroidogenic activity — it does not stimulate cortisol release. Instead, its effects are mediated primarily through robust upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), promoting neuronal survival, synaptic plasticity, and long-term potentiation. Some evidence also points to melanocortin-4 receptor (MC4R) involvement in its cognitive effects.
The practical distinction is significant: Selank tends to produce a calming, anxiolytic-first cognitive effect — it may reduce anxiety before it sharpens focus. Semax is characteristically more stimulating, enhancing attention and information processing with less sedative character. Both peptides are typically administered intranasally and have short plasma half-lives, though their neurotropic effects outlast their circulating presence. Researchers studying nootropic peptides often investigate both in combination, though their distinct receptor profiles suggest they may complement rather than duplicate each other’s effects.
Research Evidence
Both Selank and Semax have been investigated primarily in Russian and CIS-country research institutions, and both hold regulatory approval in Russia — Selank as an anxiolytic and Semax as a nootropic/neuroprotective agent. The evidence base for Semax is somewhat broader, with clinical studies conducted in stroke recovery, cognitive impairment, and optic nerve disease. A notable clinical trial demonstrated that intranasal Semax administration within the first hours after ischaemic stroke improved neurological outcomes and reduced infarct volume, leading to its approval for this indication in Russia.
Selank’s clinical evidence centers more heavily on anxiety and generalised anxiety disorder (GAD). In a controlled clinical trial, Selank demonstrated anxiolytic effects comparable to medazepam (a benzodiazepine) but without the sedation, muscle relaxation, or dependence potential. Animal research has further demonstrated its effects on gene expression in the hippocampus, particularly genes related to GABAergic signalling and neurotrophic factor pathways. Selank has also shown immunomodulatory effects in clinical studies, influencing cytokine profiles and immune cell counts.
A limitation for both peptides in the Western research context is that much of the published evidence appears in Russian-language journals, and some studies lack the methodological transparency expected by Western regulatory standards. However, the mechanistic data — BDNF upregulation for Semax, enkephalin modulation for Selank — has been replicated in well-controlled preclinical models internationally. For researchers, the key distinction remains: Semax has stronger neuroprotective and cognitive-enhancement data, while Selank has better-characterised anxiolytic and immunomodulatory profiles.
Key Differences
- Parent molecule: Selank derives from tuftsin (immunoglobulin fragment), while Semax derives from ACTH(4–10) — entirely different endogenous precursors
- Primary neurotransmitter systems: Selank modulates GABA and serotonin; Semax primarily upregulates BDNF and NGF through melanocortin pathways
- Anxiolytic vs stimulant character: Selank is characteristically anxiolytic-first; Semax tends toward cognitive stimulation without marked anxiolysis
- Immunomodulation: Selank has documented effects on cytokine balance and immune cell activity; Semax has minimal immunomodulatory data
- Clinical application in Russia: Selank is approved for anxiety disorders; Semax is approved for stroke recovery and cognitive impairment
- Neuroprotection depth: Semax scores higher for neuroprotection (6.5 vs 5.5), reflecting its stronger BDNF-mediated neuronal survival data
Frequently Asked Questions
What is the main difference between Selank and Semax?
Selank is primarily an anxiolytic peptide derived from tuftsin that modulates GABA and serotonin systems, producing a calming nootropic effect. Semax is derived from ACTH(4–10) and works mainly through BDNF upregulation and melanocortin pathways, producing a more stimulating cognitive-enhancement effect. Both are nootropic, but their character differs — Selank calms first, Semax sharpens first.
Can Selank and Semax be used together in research?
In preclinical and some clinical contexts, Selank and Semax have been investigated alongside each other. Their distinct mechanisms — GABAergic modulation versus BDNF upregulation — suggest complementary rather than redundant activity. Some Russian clinical protocols have explored concurrent administration, though robust combination-specific efficacy data remains limited.
Which peptide has stronger neuroprotective evidence?
Semax has a more robust neuroprotective evidence base, particularly from clinical studies in ischaemic stroke where it demonstrated reduced infarct volume and improved neurological outcomes. Selank has neuroprotective properties through its effects on neurotrophic gene expression and enkephalin modulation, but the clinical stroke and neurodegeneration data is less extensive than Semax’s.
Are Selank and Semax approved for medical use anywhere?
Both peptides are approved in Russia. Selank is approved as an anxiolytic agent, while Semax is approved for stroke recovery, cognitive impairment, and optic nerve disease. Neither peptide has FDA approval or EMA approval and they remain research-use compounds outside the CIS region.
How are Selank and Semax typically administered in research settings?
Both peptides are most commonly administered intranasally in research protocols. This route bypasses first-pass metabolism and provides relatively direct access to the CNS via the olfactory epithelium. Subcutaneous injection is also used in some research designs. Both have short plasma half-lives but produce neurotropic effects that persist well beyond their circulating presence.
Does Selank cause sedation like benzodiazepines?
No — one of Selank’s distinguishing features in clinical research is that it produces anxiolytic effects without the sedation, muscle relaxation, or cognitive impairment typically associated with benzodiazepines. In a comparative trial against medazepam, Selank showed similar anxiolytic efficacy without the sedative side-effect profile, and without evidence of dependence or withdrawal effects.
Which peptide is better studied overall?
Semax has a somewhat broader evidence base, with clinical trials spanning stroke, cognitive disorders, and optic neuropathy. Selank’s clinical evidence is more narrowly focused on anxiety, though it has significant immunomodulatory research as well. Both suffer from the limitation that much of their evidence base is published in Russian-language journals, limiting accessibility for Western researchers. See also: Cerebrolysin vs Semax and DSIP vs Selank for related comparisons.
References
- Zozulya AA, Sizov ME, Tsvetkova IV, et al. Anxiolytic activity of Selank. Bull Exp Biol Med. 2008;145(2):225-227. PMID: 19023985
- Eremin KO, Kudrin VS, Saranstseva SV, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552526
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. Dokl Biol Sci. 2014;459(1):338-340. PMID: 25532517
- Semenova TP, Kozlovskaya MM, Zuikov AV, et al. Comparison of the effects of Selank and its analogue on the behavior and brain monoamine levels. Neurochem J. 2009;3:43-46.
- Klimova RR, Malinovskaya SL, Masternak TB, et al. Effects of Selank on the level of cytokines under conditions of experimental immunodeficiency. Bull Exp Biol Med. 2013;155(2):230-233. PMID: 24131000